ASCO 2021 | Phase I/II trial of zenocutuzumab for tumors with NRG1 fusions

Alison M. Schram, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, summarizes the Phase I/II trial (NCT02912949) of zenocutuzumab in patients with solid tumors with NRG1 fusions. Zenocutuzumab is an anti-HER2/HER3 bispecific antibody targeting NRG1 fusion proteins and the trial included heavily pre-treated patients with pancreatic cancer, non-small cell lung cancer (NSCLC), and other solid tumors. Zenocutuzumab demonstrated promising results in all three cohorts with an acceptable safety profile and is a potential treatment for a subset of patients who have few therapeutic options. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.